Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Burris Discusses Pivotal Data, Next Steps in Breast Cancer

Gina Columbus @ginacolumbusonc
Published: Friday, Feb 01, 2019

Howard A. “Skip” Burris, MD

Howard A. “Skip” Burris, MD
Recent pivotal breast cancer data presented at the 2018 San Antonio Breast Cancer Symposium (SABCS), particularly with immunotherapy, are just the start of promising directions for researchers, said Howard A. “Skip” Burris, MD.

State of the Science Summit™ on Breast Cancer, Burris, chief medical officer of Sarah Cannon Research Institute, and president-elect of ASCO, highlighted some of the exciting updates from the 2018 SABCS and what can be expected in the breast cancer field in the year ahead.

OncLive: Reflecting on the recent breast cancer advances, how are these pivotal data informing treatment decisions?

Burris: The data coming out of SABCS and the conversations [at the State of the Science Summit™] were different than prior years, because we have exciting affirmation in all the various subtypes, as well as the various stages of breast cancer. We have promising and almost practice-changing data in HER2-positive breast cancer, TNBC, and in the realm of the estrogen receptor (ER)–positive breast cancer. It was fascinating to see, in one of the presentations at SABCS this year, a wonderful case-based discussion where Dr Cliff Hudis of ASCO moderated and Dr Hal Burstein of Dana-Farber Cancer Institute and Dr Dan Hayes of University of Michigan—all breast cancer experts—debated the strategy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication